In this real-world setting, single-dose tafenoquine was more effective at preventing P vivax recurrence in patients aged at least 16 years who were G6PD normal compared with 7-day primaquine at day 90, while overall efficacy at 180 days was similar. Th...
Prime-boost vaccinations can enhance immune responses,1 whereas chronic antigen exposure can cause immune tolerance.2 In humans, the benefits, limitations, and risks of repetitive vaccination remain poorly understood.
Prime-boost vaccinations can enhance immune responses,1 whereas chronic antigen exposure can cause immune tolerance.2 In humans, the benefits, limitations, and risks of repetitive vaccination remain poorly understood.
Since the public release of ChatGPT in November, 2022, large language models (LLMs) have been shown to offer undeniably impressive utility in medicine and health care. Their shown proficiency in providing antimicrobial advice,1 writing discharge summar...
Wilder-Smith AB, Wilder-Smith A. Determining force of infection for chikungunya to support vaccine policy development. Lancet Infect Dis 2024; published online Feb 8. https://doi.org/10.1016/S1473-3099(24)00062-8—In this Comment, the seventh sentence o...
BCG-Denmark vaccination did not reduce initial QFT Plus conversion risk in Brazilian health-care workers. This finding underscores the need to better understand tuberculosis prevention in populations at high risk.
In 2022, 1·5 million people died of tuberculosis.1 Just one licensed vaccine exists, the live attenuated Mycobacterium bovis Bacille Calmette-Guérin (BCG). BCG protects infants against disseminated disease but most people who have tuberculosis have pul...
Malaria, primarily caused by Plasmodium falciparum, has witnessed a resurgence in some countries since 2019, highlighting the need for effective vaccines. In 2021, WHO recommended the RTS,S/AS01 vaccine (GSK Vaccines, Rixensart, Belgium), the first app...
Malaria, primarily caused by Plasmodium falciparum, has witnessed a resurgence in some countries since 2019, highlighting the need for effective vaccines. In 2021, WHO recommended the RTS,S/AS01 vaccine (GSK Vaccines, Rixensart, Belgium), the first app...
Dengue is an acute mosquito-transmitted viral disease that affects an estimated 100 million people annually.1 This disease is caused by infection with any one of four dengue viruses (DENV-1, DENV-2, DENV-3, or DENV-4). Although new developments, such a...
Dengue is an acute mosquito-transmitted viral disease that affects an estimated 100 million people annually.1 This disease is caused by infection with any one of four dengue viruses (DENV-1, DENV-2, DENV-3, or DENV-4). Although new developments, such a...
An estimated 12·9 million primary dengue-virus infections occurred in India in 2017, according to the constant force of infection model.1 Vaccine-efficacy studies for quadrivalent dengue-virus vaccines conducted in other endemic countries2–4 have provi...
An estimated 12·9 million primary dengue-virus infections occurred in India in 2017, according to the constant force of infection model.1 Vaccine-efficacy studies for quadrivalent dengue-virus vaccines conducted in other endemic countries2–4 have provi...
Dengue monoclonal antibody was safe and well tolerated. It showed a dose-proportionate increase in pharmacokinetic exposure. These data support further evaluation of dengue monoclonal antibody in patients with dengue for safety and efficacy.
Dengue monoclonal antibody was safe and well tolerated. It showed a dose-proportionate increase in pharmacokinetic exposure. These data support further evaluation of dengue monoclonal antibody in patients with dengue for safety and efficacy.
Christian Holm Hansen and colleagues1 estimated the effectiveness of the XBB.1.5 updated COVID-19 vaccine against COVID-19 hospitalisation. Although their work is valuable, we have concerns regarding their negative control outcome analysis.